# Enrico Munari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4247606/publications.pdf

Version: 2024-02-01

| 83 | 3,905 | 117625 | 138484 |
|---|---|---|---|
| papers | citations | 34 h-index | 58 g-index |

| 84 | 84 | 84 | 6345 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | TSC loss is a clonal event in eosinophilic solid and cystic renal cell carcinoma: a multiregional tumor sampling study. Modern Pathology, 2022, 35, 376-385. | 5.5 | 19 |
| 2 | Program death ligandâ€1 immunocytochemistry in lung cancer cytological samples: A systematic review. Diagnostic Cytopathology, 2022, 50, 313-323. | 1.0 | 8 |
| 3 | Artificial intelligence applications for pre-implantation kidney biopsy pathology practice: a systematic review. Journal of Nephrology, 2022, 35, 1801-1808. | 2.0 | 26 |
| 4 | Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. Journal of Personalized Medicine, 2022, 12, 1073. | 2.5 | 36 |
| 5 | Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells. Journal of Allergy and Clinical Immunology, 2021, 147, 349-360. | 2.9 | 65 |
| 6 | Pediatric Tumors-Mediated Inhibitory Effect on NK Cells: The Case of Neuroblastoma and Wilmsâ€™ Tumors. Cancers, 2021, 13, 2374. | 3.7 | 11 |
| 7 | Cathepsin K: A Novel Diagnostic and Predictive Biomarker for Renal Tumors. Cancers, 2021, 13, 2441. | 3.7 | 19 |
| 8 | Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 680973. | 4.8 | 20 |
| 9 | PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. International Journal of Molecular Sciences, 2021, 22, 5123. | 4.1 | 61 |
| 10 | Challenges facing pathologists evaluating PDâ€Ł1 in head & neck squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2021, 50, 864-873. | 2.7 | 24 |
| 11 | PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy. Pathology Research and Practice, 2021, 226, 153605. | 2.3 | 28 |
| 12 | Wilmsâ€™ Tumor Primary Cells Display Potent Immunoregulatory Properties on NK Cells and Macrophages. Cancers, 2021, 13, 224. | 3.7 | 11 |
| 13 | HLA-G expression in melanomas. International Reviews of Immunology, 2021, 40, 330-343. | 3.3 | 5 |
| 14 | Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity. Frontiers in Immunology, 2021, 12, 803014. | 4.8 | 13 |
| 15 | PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation. Leukemia, 2020, 34, 932-937. | 7.2 | 26 |
| 16 | â€œInterchangeabilityâ€•of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Modern Pathology, 2020, 33, 4-17. | 5.5 | 135 |
| 17 | The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. Cancers, 2020, 12, 3285. | 3.7 | 85 |
| 18 | Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy. Molecular Cancer Therapeutics, 2020, 19, 2175-2185. | 4.1 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer. Frontiers in Immunology, 2020, 11, 2156. | 4.8 | 49 |
| 20 | Prevalence of <scp>PDâ€Ł1</scp> expression in head and neck squamous precancerous lesions: a systematic review and metaâ€analysis. Head and Neck, 2020, 42, 3018-3030. | 2.0 | 23 |
| 21 | Characterization of Human NK Cell-Derived Exosomes: Role of DNAM1 Receptor in Exosome-Mediated Cytotoxicity against Tumor. Cancers, 2020, 12, 661. | 3.7 | 96 |
| 22 | Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. Pathology, 2020, 52, 297-309. | 0.6 | 35 |
| 23 | Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28. British Journal of Pharmacology, 2020, 177, 2889-2903. | 5.4 | 10 |
| 24 | MiT Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge. Cancers, 2019, 11, 1110. | 3.7 | 79 |
| 25 | Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation. Frontiers in Immunology, 2019, 10, 1179. | 4.8 | 269 |
| 26 | PD-L1 expression in nonâ€“small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays. Human Pathology, 2019, 90, 54-59. | 2.0 | 23 |
| 27 | Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions. Frontiers in Immunology, 2019, 10, 910. | 4.8 | 54 |
| 28 | Natural killer cells: From surface receptors to the cure of highâ€risk leukemia (Ceppellini Lecture). Hla, 2019, 93, 185-194. | 0.6 | 11 |
| 29 | Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PDâ€1 receptor. International Journal of Cancer, 2019, 145, 1660-1668. | 5.1 | 65 |
| 30 | Clinical implication of the mammalian target of rapamycin pathway in upper tract urothelial carcinoma with negative GATA binding proteinÂ3 expression. International Journal of Urology, 2019, 26, 678-679. | 1.0 | 2 |
| 31 | Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cellular and Molecular Immunology, 2019, 16, 430-441. | 10.5 | 327 |
| 32 | PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua. Mucosal Immunology, 2019, 12, 624-631. | 6.0 | 45 |
| 33 | PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer. Journal of Immunotherapy, 2019, 42, 269-273. | 2.4 | 10 |
| 34 | PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression. OncoImmunology, 2019, 8, 1557030. | 4.6 | 76 |
| 35 | Insulin-like growth factor-1 receptor expression in upper tract urothelial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 21-27. | 2.8 | 12 |
| 36 | Expression of programmed cell death ligand 1 in nonâ€“small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay. Cancer Cytopathology, 2019, 127, 52-61. | 2.4 | 49 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Helper Innate Lymphoid Cells in Human Tumors: A Double-Edged Sword?. Frontiers in Immunology, 2019, 10, 3140. | 4.8 | 9 |
| 38 | Exploiting Human NK Cells in Tumor Therapy. Frontiers in Immunology, 2019, 10, 3013. | 4.8 | 37 |
| 39 | Proximal CD13 Versus Distal GATA-3 Expression in Renal Neoplasia According to WHO 2016 Classification. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 316-323. | 1.2 | 6 |
| 40 | Non-small cell lung cancer: land of conquest for immunotherapy. Journal of Thoracic Disease, 2018, 10, 5184-5185. | 1.4 | 0 |
| 41 | Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes?. Immunology Letters, 2018, 201, 14-19. | 2.5 | 50 |
| 42 | Predicting progression in T1 nonâ€muscleâ€invasive bladder cancer: back to histology. BJU International, 2018, 122, 914-915. | 2.5 | 2 |
| 43 | Human Innate Lymphoid Cells: Their Functional and Cellular Interactions in Decidua. Frontiers in Immunology, 2018, 9, 1897. | 4.8 | 62 |
| 44 | PD-L1 Expression Heterogeneity in Nonâ€“Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. Journal of Thoracic Oncology, 2018, 13, 1113-1120. | 1.1 | 135 |
| 45 | NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines. Cancer Research, 2018, 78, 3913-3925. | 0.9 | 53 |
| 46 | PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Nonâ€“Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs. American Journal of Surgical Pathology, 2018, 42, 1384-1389. | 3.7 | 77 |
| 47 | PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263. Oncotarget, 2018, 9, 30465-30471. | 1.8 | 26 |
| 48 | MicroRNA expression profiling of Xp11 renal cell carcinoma. Human Pathology, 2017, 67, 18-29. | 2.0 | 25 |
| 49 | Strong association of insulin-like growth factor 1 receptor expression with histologic grade, subtype, and HPV status in penile squamous cell carcinomas: a tissue microarray study of 112 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 695-701. | 2.8 | 5 |
| 50 | Validation of 34betaE12 immunoexpression in clear cell papillary renal cell carcinoma as a sensitive biomarker. Pathology, 2017, 49, 10-18. | 0.6 | 30 |
| 51 | Cathepsin K Expression in Castration-Resistant Prostate Carcinoma: A Therapeutical Target for Patients at Risk for Bone Metastases. International Journal of Biological Markers, 2017, 32, 243-247. | 1.8 | 10 |
| 52 | PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. Oncotarget, 2017, 8, 90123-90131. | 1.8 | 89 |
| 53 | Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary Malignancies. PLoS ONE, 2016, 11, e0146302. | 2.5 | 27 |
| 54 | Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome. Histopathology, 2016, 68, 422-432. | 2.9 | 62 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated With Penile Cancer Progression. Urology, 2016, 92, 51-56. | 1.0 | 9 |
| 56 | Group 3 innate lymphoid cells regulate neutrophil migration and function in human decidua. Mucosal Immunology, 2016, 9, 1372-1383. | 6.0 | 99 |
| 57 | Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. Targeted Oncology, 2016, 11, 345-351. | 3.6 | 56 |
| 58 | Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells â€œin vitroâ€•and correlating with progression â€œin vivoâ€• Oncotarget, 2016, 7, 74189-74202. | 1.8 | 21 |
| 59 | Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder. PLoS ONE, 2015, 10, e0127908. | 2.5 | 21 |
| 60 | Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. PLoS ONE, 2015, 10, e0131245. | 2.5 | 42 |
| 61 | Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 204.e1-204.e7. | 1.6 | 34 |
| 62 | Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ TÂCells in Urothelial Carcinoma. Urology, 2015, 85, 703.e1-703.e6. | 1.0 | 122 |
| 63 | Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases. Human Pathology, 2015, 46, 761-766. | 2.0 | 10 |
| 64 | Human papillomavirus infection and immunohistochemical p16INK4a expression as predictors of outcome in penile squamous cell carcinomas. Human Pathology, 2015, 46, 532-540. | 2.0 | 43 |
| 65 | Cyclin A1 expression predicts progression in pT1 urothelial carcinoma of bladder: a tissue microarray study of 149 patients treated by transurethral resection. Histopathology, 2015, 66, 262-269. | 2.9 | 15 |
| 66 | <sup>18</sup>F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 1003-1010. | 5.0 | 180 |
| 67 | PDL1 status in muscle-invasive urothelial carcinoma in the context of neoadjuvant cisplatin-based chemotherapy.. Journal of Clinical Oncology, 2015, 33, 300-300. | 1.6 | 1 |
| 68 | Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.. Journal of Clinical Oncology, 2015, 33, 336-336. | 1.6 | 3 |
| 69 | Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases. Histopathology, 2014, 64, 863-871. | 2.9 | 23 |
| 70 | Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Human Pathology, 2014, 45, 1130-1138. | 2.0 | 61 |
| 71 | Insulin-like Growth Factor-1 Receptor Overexpression Is Associated With Outcome in Invasive Urothelial Carcinoma of Urinary Bladder: A Retrospective Study of Patients Treated Using Radical Cystectomy. Urology, 2014, 83, 1444.e1-1444.e6. | 1.0 | 19 |
| 72 | ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. Human Pathology, 2014, 45, 2233-2239. | 2.0 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. Journal of Hematology and Oncology, 2014, 7, 47. | 17.0 | 66 |
| 74 | Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms. Human Pathology, 2014, 45, 244-248. | 2.0 | 22 |
| 75 | An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine. Oncotarget, 2014, 5, 5218-5233. | 1.8 | 19 |
| 76 | TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine. Cancer Research, 2013, 73, 7162-7167. | 0.9 | 214 |
| 77 | Immunohistochemical expression of SALL4 in hepatocellular carcinoma, a potential pitfall in the differential diagnosis of yolk sac tumors. Human Pathology, 2013, 44, 1293-1299. | 2.0 | 38 |
| 78 | Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma. Human Pathology, 2013, 44, 2668-2676. | 2.0 | 23 |
| 79 | The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases. Human Pathology, 2013, 44, 2690-2695. | 2.0 | 42 |
| 80 | Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma. Cell Cycle, 2013, 12, 1058-1070. | 2.6 | 36 |
| 81 | Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 677-685. | 2.8 | 9 |
| 82 | Oncocytic papillary renal cell carcinoma: potential pitfall in small enucleation. Pathologica, 2012, 104, 98-100. | 3.4 | 0 |
| 83 | Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Modern Pathology, 2011, 24, 1313-1319. | 5.5 | 112 |